Jarbis 10 Tablet contains Empagliflozin 10 mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the proximal renal tubules, Empagliflozin reduces glucose reabsorption, promoting urinary glucose excretion and thereby lowering plasma glucose levels. This mechanism contributes to improved glycemic control when used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Jarbis 10 is also associated with additional benefits including modest reductions in body weight and blood pressure, which may be advantageous in patients with comorbid cardiovascular risk factors. Clinical studies have demonstrated its efficacy in reducing HbA1c levels and improving overall metabolic parameters. The medication is generally well tolerated; however, potential adverse effects include urinary tract infections, genital mycotic infections, and increased urination. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to the active substance. Regular monitoring of renal function and hydration status is recommended during therapy. Jarbis 10 should be prescribed as part of a comprehensive diabetes management plan including diet and exercise.